



Luxembourg, 12 April 2020

<p style="text-align: center;"><b>Scientific Committee on Consumer Safety (SCCS)</b> <b>15<sup>th</sup> Plenary meeting</b></p>
---

30-31 March 2021

**Minutes**

**1. Welcome and apologies, approval of the minutes of the previous plenary meeting/new agenda and declaration of interests**

The Chair welcomed all participants, in particular the SCHEER representative and DG GROW F2 colleague. The agenda was adopted. Two apologies were received the first day and none the second day.

The minutes of the previous plenary meeting were adopted by the SCCS via written process and published on the website:

[https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/minutes\\_plenary\\_en](https://ec.europa.eu/health/scientific_committees/consumer_safety/minutes_plenary_en)

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matters on the agenda.

**2. List of points discussed and conclusions**

**2.1 General information from GROW**

- The EU publication office released a new consolidated version of the Cosmetics Regulation (updated until Dec 2020): <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02009R1223-20201203>

EN :<https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02009R1223-20201203&from=EN>

- GROW informed about the outcome of the re-organisation. Cosmetics is now part of unit F2 ‘**Bioeconomy, chemicals, cosmetics**’.  
New general mailbox is [GROW-F2@ec.europa.eu](mailto:GROW-F2@ec.europa.eu)

**2.2 New mandate(s)**

1. The following mandates have been adopted by written procedure on 8 March and published on the website:  
[https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/requests\\_en](https://ec.europa.eu/health/scientific_committees/consumer_safety/requests_en)

- Four new mandates for endocrine disrupting (ED) substances from Group A (4-Methylbenzylidene camphor/4-MBC, Butylated Hydroxytoluene/ BHT, Kojic acid, Genistein and Daidzein)
- A new mandate for the revision of the Vitamin A Opinion

The rapporteurs selected by the SCCS have been appointed by the Commission.

2. SCHEER asked the SCCS for an additional representative in their new WG on TiO<sub>2</sub> in toys. The SCCS agreed.

### 2.3. Draft opinions

#### *Nanomaterials in cosmetic ingredients*

One final Opinion has been adopted and will be published:  
[SCCS - Opinions 2016 - 2021 | Public Health \(europa.eu\)](#)

#### **Hydroxyapatite (nano)** – submission II

Two preliminary Opinions have been adopted and will be published for comments:  
[https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/opinions\\_en](https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions_en)

- Gold (nano) -Colloidal Gold (nano) [, Gold Thioethylamino Hyaluronic Acid (nano) and Acetyl heptapeptide-9, Colloidal gold (nano)
- Platinum (nano) -Colloidal Platinum (nano) and Acetyl tetrapeptide-17 Colloidal Platinum (nano)

A progress report was provided on HAA-299 nano, which will be further discussed at the next April WG meeting.

#### *Cosmetic Ingredients*

A progress report was provided on:

1. **Methyl salicylate** (methyl 2-hydroxybenzoate). Tasks have been allocated to the members and a revised version of the draft preliminary Opinion will be discussed at the next April WG meeting.
2. **C054 hair dye**. The Applicant sent additional study to the SCCS that is still under assessment. Tasks have been allocated to the members and a revised version of the draft preliminary Opinion will be discussed at the next April WG meeting.
3. **Prostaglandin and analogues**. Relevant data are lacking. A draft preliminary Opinion will be discussed at the next WG meeting.
4. **Formaldehyde releasers**. A first draft of the preliminary Advice will be prepared for discussion at the next April WG meeting.

## ***Methodology***

The Chair of the WG on methodology presented the final version of **the 11<sup>th</sup> Revision of the SCCS Notes of Guidance (NoG)**. Last contributions received from the members were discussed and agreed on.

The whole NoG have been revised and updated with a particular emphasis on the following:

- Inhalation models
- In silico methodology for genotoxicity/carcinogenicity
- General updating of NAMs
- Scientific concerns for the safety of the nanomaterials
- Update of ED section
- Discussion on uncertainty factors
- Updating of references in general
- Appendix 1: complying with the testing & marketing bans
- Appendix 9: guidelines on microbiological quality of the finished product
- Appendix 10: free access to in silico mutagenicity/genotoxicity databases
- Appendix 11: inhalation parameterisation
- Appendix 12: Lifetime Cancer Risk Approach
- Appendix 13: PoD used for TTC derivation

The final document was adopted and will be published. There is no commenting period foreseen as this is an SCCS living document, regularly updated.

Any comment /remark may always be sent to the SCCS mailbox: [SANTE-C2-SCCS@ec.europa.eu](mailto:SANTE-C2-SCCS@ec.europa.eu)

## **2.4 Comments on opinions**

### ***Cosmetic Ingredients***

The following final Opinion has been adopted together with the SCCS responses to comments received during the public consultation. Both documents will be published on the website under the public consultation page:

[Public consultation on BPA in clothing articles | Public Health \(europa.eu\)](#)

#### **1. BPA in clothing**

The following final Opinions have been adopted and will published on the website:

[SCCS - Opinions 2016 - 2021 | Public Health \(europa.eu\)](#)

#### **2. Resorcinol**

#### **3. Propylparaben**

#### **4. Octocrylene**

#### **5. Benzophenone-3**

#### **6. Addendum to the scientific Opinion SCCS/1613/19 on the safety of aluminium in cosmetic products - Submission II**

The SCCS responses to comments received during the commenting period have been adopted and will be sent to respective recipients.

A progress report was provided on:

**Homosalate:** the Applicant sent additional studies to the SCCS that are still under assessment. Tasks have been allocated to the members and a revised version of the final Opinion will be discussed at the next WG meeting.

### 3. Information from Commission and member of the SCCS

The SCCS Chair gave the floor for an update on the state of play of the following issues:

#### From the Commission

- The list of mandates/opinions for the SCs have been circulated
- PARC project: the ‘framing’ of this EU research project is ongoing. At this stage, upon request of the SCCS Secretariat, SANTE coordinator has approached DG RTD and ANSES-FR (lead PARC coordinators) to note the relevance of SCCS as a stakeholder.  
See: [ec\\_rtd\\_he-partnerships-chemical-risk-assessment.pdf \(europa.eu\)](#)
- The Secretariat informed about the nomination of one SCCS and one SCHEER member to represent their Committee in GROW WG on the definition of nanomaterials.
- ‘One substance – one assessment’ WG set by the recent adopted Chemical Strategy: the SCCS Secretariat provided a feedback about their first internal meeting.
- Cosmetics Europe (CoE) is planning to organise their annual event on 16 June via video/web. CoE invited the SCCS Vice-Chair to present changes in the 11th revision of the SCCS Notes of Guidance (NoG) and the SCCS Secretariat to discuss the situation/future of the work of the SCs. GROW is also invited to join.
- A written report of all the presentations and discussions of the Second Forum on Endocrine Disruptors (December 2020) is now available via the link below. On the same page, one will also find the video recordings and the presentations.  
[https://ec.europa.eu/environment/events/second-annual-forum-endocrine-disruptors\\_en](https://ec.europa.eu/environment/events/second-annual-forum-endocrine-disruptors_en)

#### From the Members

- “Putting Science into Standards” Workshop on Organ-on-Chip is co-organised by JRC and CEN/CENELEC on 28-29 April 2021. SCCS Vice-Chair is planning to participate on behalf of the SCCS. See: [organ\\_on\\_chip\\_agenda\\_no\\_agenda.pdf \(cvent.com\)](#)
- The SCCS does not need more external experts for the moment. The SCCS will reassess the situation regularly, in particular with regard to the ED substances mandated, and inform the Secretariat accordingly. Any external expert can still apply in the EU database of external experts: [Database of Experts | Public Health \(europa.eu\)](#)

#### **4. Next working group meetings:**

- WG Cosmetic ingredients: 23 and 27 April + 21 and 26 May 2021 + 19 July + 8-9 September (to be confirmed at April WG meeting)
- WG Nanomaterials in cosmetics: 14 April and 20 May 2021
- WG Methodology: 12 or 28 May 2021 (to be confirmed)

#### Next plenary meetings:

- 24-25/06/2020
- 26-27/10/2021

#### **5. A.O.B**

The Chair of the nano WG asked DG GROW for an update of the potential new file on silica. DG GROW did not receive any information yet from applicant(s) and will keep the SCCS informed.